Canada House Wellness Group Inc. (CSE: CHV) (“
Canada
House” or the “
Company”), a fully
integrated medical cannabis company, is pleased to provide an
update on clinic expansion by its wholly owned subsidiary Canada
House Clinics Inc. (“
CHC”).
CHC will open its first clinics in Toronto and
Halifax, relocate its Petawawa clinic to a larger space and launch
a new clinic model in Edmonton. Once the new spaces open, CHC will
operate 14 clinics across Canada.
“We strive to continuously improve the patient
experience,” said Alex Kroon, President, Canada House Clinics.
“There is a process involved in cannabinoid therapy and patients
are looking for guidance. CHC is committed to offering different
models to meet patient needs and increase access for all Canadians
requiring medical cannabis therapy.”
Canada House Clinics’ first Toronto clinic will
open on June 17, 2019 in the Champagne Centre (a multidisciplinary
medical complex) in North York. The Champagne Centre is an
innovative 270,000 square foot health, sports, and wellness complex
that includes the PolyClinic Family and Specialty Medicine
Facility.
CHC will open its Halifax clinic on July 3,
2019, building on the strong network of clinics already operating
in Atlantic Canada.
CHC moved its Petawawa location to a larger
clinic in the same area on June 10, 2019.
This summer in Sherwood Park, Alberta, CHC will
open its first location within a third-party medical clinic (an
embedded clinic model). CHC will operate an office inside an
existing medical clinic. Doctors can offer cannabinoid therapy to
their patients. This first embedded clinic will be CHC’s second
location in the Edmonton area. CHC plans to replicate this embedded
clinic model in other cities.
“Our clinic footprint continues to grow across
Canada,” said Chris Churchill-Smith, CEO, Canada House. “Smart,
targeted clinic expansion will reduce our operating expenses,
continue to accelerate growth, drive profitability, build
shareholder value and help us continue to meet the needs of
Canadian patients.”
About Canada House Wellness Group
Inc.
Canada House Wellness Group Inc. is the parent
company of Abba Medix Corp., a Licensed Producer in Pickering,
Ontario that produces high quality medical grade cannabis; Canada
House Clinics Inc., with clinics across the country that work
directly with primary care teams to provide specialized cannabinoid
therapy services to patients suffering from complex medical
conditions; and Knalysis Technologies, a provider of fully
customizable, cloud-based software that links physician, provider,
and patient to data that supports treatment with medical
cannabis.
Canada House Wellness Group’s goal is to become
the leading cultivator of premium craft cannabis and provider of
cannabinoid therapy, targeting the medical cannabis markets
globally.
For more information please visit
www.canadahouse.ca.
For further information, please
contact:
Liana Del Medico, Director of
Communications & Investor Relations Canada House
Wellness Group Inc.289-980-3584 liana.delmedico@canadahouse.ca
Cautionary Statement Regarding
Forward-Looking Information. This press release contains
forward-looking statements, including statements that relate to,
among other things, the Company’s clinic, production and technology
businesses, its future plans, the Company’s markets, objectives,
goals, strategies, intentions, beliefs, expectations and estimates,
and can generally be identified by the use of words such as “may”,
“will”, “could”, “should”, “would”, “likely”, “possible”, “expect”,
“intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective”
and “continue” (or the negative thereof) and words and expressions
of similar import. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, such statements involve risks and uncertainties, and
undue reliance should not be placed on such statements. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Material assumptions used to develop forward-looking information in
this news release include, among other things, the regulations
related to cannabis use under the Access to Cannabis for Medical
Purposes Regulations and the act respecting cannabis and to amend
the Controlled Drugs and Substances Act, the Criminal Code and
other Acts, passed by the Canadian Federal government, making
cannabis legal for recreational use by October 17, 2018; Company
liquidity and capital resources, including the availability of
additional capital resources to fund its activities; level of
competition; the ability to adapt products and services to the
changing market; the ability to attract and retain key executives;
and the ability to execute strategic plans. Additional information
about material factors that could cause actual results to differ
materially from expectations and about material factors or
assumptions applied in making forward-looking statements may be
found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as
in other public disclosure documents filed with Canadian securities
regulatory authorities. The Company does not undertake any
obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a
result of new information, future events or otherwise, except as
required by law.
Neither the CSE nor its Regulation Services
Provider (as that term is defined in the policies of the CSE)
accepts responsibility for the adequacy or accuracy of this
release.
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From May 2024 to Jun 2024
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From Jun 2023 to Jun 2024